The pharmaceutical industry is experiencing its own “DeepSeek moment,” according to science writer Hiya Jain. Just as the upstart AI breakthrough caught Silicon Valley off-guard, China is emerging as a formidable force in drug development ...

Developing high-quality, safe, and effective drugs is a complex process that requires varied scientific skills and stringent regulatory assessments. Drug development is a process that spans many years, from the initial phase of identifying potential drug ...

In 2021, Malachite initiated a corporate restructuring plan to create two parallel pathways for shareholder value creation and optimize the present value of its more than $20 million of net operating losses. As part of this corporate restructuring ...

Rallybio has agreed to sell its interest in a drug-development plan seeking to treat a rare genetic bone disease to its joint-venture partner Recursion Pharmaceuticals for up to $25 million. The New Haven, Conn., clinical-stage biotechnology company said ...

The Congressional Budget Office (CBO) informs Congress about the costs or revenue changes associated with proposed legislation, a challenging enough task on its own. Sometimes, the CBO is asked to estimate effects beyond budget impact such as the ...

TAIPEI, Taiwan--(BUSINESS WIRE)--QPS, a leading global contract research organization (CRO) specializing in preclinical and clinical drug development services, is pleased to announce the expansion of its pharmacology disease models portfolio to include ...

In 2026, there are fewer prescription drug plans in Medicare Part D and higher premiums, even when offset by a multi-billion-dollar government premium subsidy; this degradation of the Part D market is likely attributable to the Inflation Reduction Act (IRA).